

AD _____

Award Number: DAMD17-01-1-0142

TITLE: Linking Sister Chromatid Cohesion to Apoptosis and Aneuploidy
in the Development of Breast Cancer

PRINCIPAL INVESTIGATOR: Debananda Pati, Ph.D.

CONTRACTING ORGANIZATION:

Baylor College of Medicine
Houston, Texas 77030

REPORT DATE: July 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030203 068

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2002	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 01 - 30 Jun 02)	
4. TITLE AND SUBTITLE Linking Sister Chromatid Cohesion to Apoptosis and Aneuploidy in the Development of Breast Cancer			5. FUNDING NUMBERS DAMD17-01-1-0142	
6. AUTHOR(S) Debananda Pati, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030 Email: pati@bcm.tmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) <p>The purpose of the study is to identify the effector molecules that act as a link between cell proliferation, cell survival and chromosomes stability. We have hypothesized that chromosomal segregation and apoptotic pathways are linked and have a role in the development of aneuploidy in breast tumors. Rad21 is one of the major cohesin subunits that holds sister chromatids together until anaphase, when proteolytic cleavage by separase, allows chromosomal separation. We show that cleavage of human Rad21 (hRad21) also occurs during apoptosis. Induction of apoptosis in multiple human cell lines results in the early generation of 64 kDa and 60 kDa carboxy terminal hRad21 cleavage products. We biochemically mapped a apoptotic cleavage site at residue Asp (D)²⁷⁹ of hRad21. This apoptotic cleavage site is distinct from mitotic cleavage sites previously described. hRad21 is a nuclear protein, however, the cleaved 64 kDa carboxy-terminal product is translocated to the cytoplasm early in apoptosis before chromatin condensation and nuclear fragmentation. Overexpression of the 64 kDa cleavage product results in apoptosis in MCF-7 breast cancer cells. Given the role of hRad21 in chromosome cohesion, the cleaved C-terminal product and its translocation to the cytoplasm may act as a nuclear signal for apoptosis. Deregulation of Rad21 cleavage may play a role in breast cancer pathogenesis.</p>				
14. SUBJECT TERMS breast cancer, pathobiology, cell cycle, apoptosis, aneuploidy, sister chromatid cohesion				15. NUMBER OF PAGES 37
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusions.....	8
References.....	9
Appendices.....	11
Appendix-I (Work accomplished)	11
Appendix-II (Manuscript in revision)	12
Appendix-III (Abstract)	37

Introduction

Cell death by apoptosis plays an essential role in normal development and physiology in the breast⁹ as well as in the development of breast Cancer^{19,22}. The degree of apoptosis can be an important factor in both the progression of breast cancer and the response to treatment^{5,11}. A high apoptotic index (number of apoptotic cells per square millimeter of neoplastic tissue) is related to malignant cellular features and is an indicator of invasiveness and cell proliferation in breast cancer¹¹. Treatment of breast cancer is improved by increasing the percentage of cells undergoing apoptosis. Thus, cell cycle progression and control of apoptosis are thought to be intimately linked processes. Activation of the cell cycle plays a significant role in the regulation of apoptosis⁸; in some cell types and under certain conditions, apoptosis has been shown to occur only at specific stages of the cell cycle¹⁰. Mitosis and apoptosis are closely interrelated¹². Although proteins that regulate apoptosis have been implicated in restraining cell cycle entry⁶ and controlling ploidy¹⁴, the effector molecules at the interface between cell proliferation and cell survival have remained elusive. **The purpose of the study is to identify the effector molecules that act as a link between cell proliferation, cell survival and chromosomal stability. We have hypothesized that chromosomal segregation and apoptotic pathways are linked and have a role in the development of aneuploidy in breast tumors. Human Rad21, a protein that establishes and maintains sister chromatid cohesion during mitosis may provide a link between cell division and cell death, and cleavage of Rad21 may signal subsequent events of cell death including DNA degradation. We also hypothesize that hRad21 helps maintain chromosomal stability in mammary cells and its dysregulation results in breast cancer formation.** To test these hypotheses we have the following **specific aims**: 1) Evaluate the role of hRad21 in the apoptotic response and the role of apoptotic proteins on cleavage of hRad21. 2) Determine the expression and localization of hRad21 protein and mRNA in normal and malignant breast carcinoma cell lines and tumor specimens with known levels of aneuploidy.

Following is the annual progress report for the first year of the project. We have made substantial progress on the first technical objective i.e. role of Rad21 in apoptotic response. Our results indicate that in addition to establishing and maintaining sister chromatid cohesion during mitosis, hRad21 plays a direct role in apoptosis, and its cleavage during apoptosis may act as a nuclear signal to initiate cytoplasmic events involved in the apoptotic pathway. A manuscript describing this work (see appendix 1) was submitted to the Journal Molecular and Cellular Biology on May 8, 2002, and is currently under revision¹⁸. In accordance with the approved statement of work, tasks for technical objectives 1A have been completed and 1B, 1C and objective 2 are currently underway (Appendix 2).

Body of the report

Rad21 is one of the major cohesin subunits that holds sister chromatids together until anaphase, when proteolytic cleavage by separase, a caspase-like enzyme, allows chromosomal separation. During the postdoctoral research fellowship funded by the US Army Breast Cancer Research program (DAMD 12-96-1-6087), the PI isolated the cDNA encoding human Rad21 (Scc1/Mcd1 in budding yeast) in a two-hybrid screen as an

interactor of human Cdc34 ubiquitin-conjugating enzyme^{16,17}. Analyses of Rad21 function in fission yeast, *S. pombe*, and (Scc1/Mcd1 in budding yeast, *S. cerevisiae*) have demonstrated that the nuclear phosphoprotein is required for appropriate chromosomal segregation during the normal mitotic cell cycle and double-strand break repair after DNA damage^{3,15}. In budding yeast, loss of cohesion at the metaphase-anaphase transition is accompanied by proteolytic cleavage of the Scc1/Mcd1 protein^{15,21}, followed by its dissociation from the chromatids^{13,15}. Cleavage depends on Esp 1 protein (called separin/separase), which is complexed with inhibitor, Pds 1 (also known as securin), before anaphase⁴. In summary, the **Scc 1/Mcd 1/Rad21 plays a critical role in the eukaryotic cell division cycle by regulating sister chromatid cohesion and separation at the metaphase to anaphase transition**. In mammals, however, little is known about the role of Rad21 cleavage during sister chromatid separation or its impact in human malignancies.

Aim 1) Role of Rad21 in apoptotic response: Tasks completed as a part of this objective, clearly demonstrate a role of hRad21 in the apoptotic response and cleavage of the hRad21 protein in human cells by a caspase-like activity. We have shown that cleavage of human Rad21 (hRad21) also occurs during apoptosis induced by diverse stimuli including DNA-damaging agents (ionizing radiation and topoisomerase inhibitors) and/or non-DNA-damaging agents (prostaglandin, proteasome inhibitor, cycloheximide treatment, and cytokine withdrawal). Induction of apoptosis in multiple human cell lines results in the early (4 hours post insult) generation of 64 kDa and 60 kDa carboxy terminal hRad21 cleavage products. We biochemically mapped an apoptotic cleavage site at residue Asp (D)²⁷⁹ of hRad21. This apoptotic cleavage site is distinct from mitotic cleavage sites previously described⁶. Although hRad21 is cleaved *in vitro* at D²⁷⁹ by caspase-3 and -7, indirect evidence suggests involvement of a novel caspase or caspase-like molecule in hRad21 cleavage. hRad21 is a nuclear protein, however, the cleaved 64 kDa carboxy-terminal product is translocated to the cytoplasm early in apoptosis before chromatin condensation and nuclear fragmentation. Overexpression of the 64 kDa cleavage product results in apoptosis in Molt4 leukemic t-cells and MCF-7 breast carcinoma cells. Given the role of hRad21 in chromosome cohesion, the cleaved C-terminal product and its translocation to the cytoplasm may act as a nuclear signal for apoptosis. In summary, we show that cleavage of a cohesion protein and translocation of the C-terminal cleavage product to the cytoplasm are early events in the apoptotic pathway and cause amplification of the cell death signal in a positive feed back manner by activation of more caspases. Detailed description of the results can be obtained in the attached manuscript (see appendix 2).

Aim 2) Expression and localization of Rad21 Protein and mRNA in normal and malignant breast carcinoma cell lines and tumor samples: We have examined the expression pattern of Rad21 in a variety of breast cancer cell lines, and Rad21 was found to be overexpressed in all breast cancer cell lines except BT20. Expression pattern of Rad21 in breast cancer cell lines MCF7, MDA-MB-157, MDA-MB-231, MDA-MB-436, BT-20, HBL100, and SKBR-3 was studied. In these cells, Rad21 appeared to have altered expression patterns. Compared to normal human mammary epithelial cells (H-MEC), Rad21 mRNA is overexpressed in all the cells tested, except for BT20, where its

expression was found to be considerably down regulated. Expression and localization of the hRad21 protein in normal and malignant breast cancer cells are presently being performed using immunocytochemistry and immunofluorescence techniques. hRad21 efficiently localizes to the nucleus of various mammalian cells assayed by immunofluorescence staining using either the affinity purified polyclonal or monoclonal hRad21 antibodies. Currently, about 250 breast tumor specimens with unknown status for aneuploidy, estrogen receptor, and a number of other markers with appropriate controls available from the Allred lab at Baylor Breast Cancer Center are being used to study the expression and localization of Rad21 protein in these cells using immunohistochemistry^{1,2}/immunofluorescence techniques already established in our lab. The Allred lab has assisted us in developing a robust assay to immunolocalize the hRad21 protein using monoclonal hRad21 antibody. Since most referral specimens are fixed 10% neutral buffered formalin and processed at variable rates and times, increased sensitivity and standardization of the assay is achieved through the use of heat induced antigen retrieval post-deparaffinization. Endogenous nonspecific protein blocking then follows. Subsequently, incubation with the primary antibody (monoclonal hRad21) is preformed, followed by a biotinylated secondary antibody incubation directed against the mouse. These are then followed by incubation in horseradish peroxidase (HRP)-labeled streptavidin, which then binds to the biotin label of the secondary antibody. The entire reaction is then visualized by a incubation with 3,3 diaminobenzidine which, in the presence of HRP, produces a brown reaction product at the site of the antigen-antibody interaction. Enhancement of the reaction product is achieved by the addition of the heavy metal osmium tetroxide, which increases the tone of the reaction product and elevates the signal: noise ratio of the assay. Scoring of immunostained slides for hRad21 expression is preformed according to the protocol described for Bcl-2 expression in breast tumor specimens² and based on the proportion of cells staining positive, described by the Allred laboratory.

Due to difficulty in isolating RNA from frozen tumor specimens, expressions of *hRAD21* mRNA will be investigated in a subset of breast tumors with Northern blot analysis. The more sensitive RNase protection assay will be correlated with hRad21 protein levels. Quantitation of *hRad21* message will be preformed using a ³²p-labeled probe detected on a Molecular Dynamics STORM imager. Choice of normal control for expression studies is more difficult. We will use both the MCF-10F cell line and normal human mammary epithelial cells (H-MEC) as controls. In parallel, the expression of hRad21 will be analyzed in the same set of breast tumor specimens in Western blot analysis using the monoclonal hRad21 antibody. Bound primary antibodies will be detected with IRD800 dye-labeled appropriate species-specific secondary antisera and signal was visualized on a Li-Cor (Lincoln, NE) Odyssey infrared scanner. Normalization for loading will be preformed by comparing the expression of housekeeping genes as actin (for protein) and GADPH (for RNA).

Studies in progress: Cleavage of hRad21 appears to be an early event in the apoptotic pathway. The immunofluorescence experiments clearly demonstrate the translocation of the hRad21 C-terminal cleavage products to the cytoplasm early (3-4h post insult) in apoptosis. C-terminal hRad21 cleavage product is pro-apoptotic as determined by

increased caspase-3 activity and apoptotic morphology and that its translocation to the cytoplasm may play a role in promoting apoptosis. Currently we have therefore focused our efforts to study the mechanism of the Carboxy-terminal hRad21-induced apoptosis.

A preliminary set of studies indicated that the expression of the Rad21 protein in specific cellular compartments lead to the introduction of apoptosis. Current experiments explore this further by forcing the expression of the full-length as well as the cleaved Rad21 protein into the cytoplasmic compartment using HIV-TAT expression system developed by Dowdy and colleagues²⁰. TAT-mediated protein transduction has recently been widely used to manipulate cellular processes by the introduction of full-length or mutant proteins in a concentration dependent manner into 100% of cells²⁰. We have obtained these reagents and the protocol from the Dowdy lab. The *RAD21* cDNA encoding the full length and the cleaved hRad21 proteins were cloned in-frame downstream of the N-terminal 6XHis-Tat-PTD sequence in the pTat bacterial expression vector. However, we have not been successful in purifying the fusion protein in sufficient quantities. Recombinant Tat-Rad21 fusion protein appeared to be expressed in insoluble form in *E. coli*; and may be present in the bacterial inclusion bodies. Urea was used to solubilize the protein stored in inclusion bodies. Following purification over a Ni²⁺-NAT agarose affinity column in 8M urea, the urea was removed by single step ion-exchange chromatography. However, the yield of the purified Tat-Rad21 fusion proteins was very low and was not enough to use in the protein transduction experiments. Currently we are repeating these experiments with a modified Tat-C-terminal Rad21 fusion construct. As an alternate to the TAT system we are also using IMPACT-CN one-step purification of recombinant protein system (New England BioLabs, Inc. Beverly, MA) to produce the recombinant Rad21 proteins. IMPACT (Intein Mediated Purification with an Affinity Chitin-binding Tag) is a novel protein purification system which utilizes the inducible self-cleavage activity of a protein splicing element (termed intein) to separate the target protein from the affinity tag. It distinguishes itself from all other purification systems by its ability to purify, in a single chromatographic step, a native recombinant protein without the use of a separate protease. Recombinant Rad21 will be used for protein transduction experiments. The apoptotic response of mammary cells transduced with the cleaved Rad21 in comparison to the wild type (WT) Rad21 will be examined thoroughly using apoptotic assays including detection of DNA laddering and special staining techniques that are based on *in situ* labeling of the fragmented DNA (Terminal deoxynucleotidyl transferase mediated UTP Nick End-Label (TUNEL) staining). These experiments will be instrumental in identifying if Rad21 cleavage is essential for induction of apoptosis and/or sensitizes cells to undergo apoptosis after exposure to apoptotic agents.

Key research Accomplishments

- Cleavage of human Rad21 (hRad21) cohesin occurs during apoptosis induced by diverse stimuli. Induction of apoptosis in multiple human cell lines results in the early (4 hours post insult) generation of 64 kDa and 60 kDa carboxy terminal hRad21 cleavage products.
- Apoptotic cleavage site of hRad21 is mapped at residue Asp (D)²⁷⁹. This apoptotic cleavage site is distinct from mitotic cleavage sites of hRad21.

- Although hRad21 is cleaved *in vitro* at D²⁷⁹ by caspase-3 and -7, indirect evidence suggests involvement of a novel caspase or caspase-like molecule in hRad21 cleavage.
- hRad21 is a nuclear protein, however, the cleaved 64 kDa carboxy-terminal product is translocated to the cytoplasm early in apoptosis before chromatin condensation and nuclear fragmentation.
- Overexpression of the 64 kDa cleavage product results in apoptosis in MCF-7 breast cancer cells. Given the role of hRad21 in chromosome cohesion, the cleaved C-terminal product and its translocation to the cytoplasm may act as a nuclear signal for apoptosis.
- hRad21 is differentially expressed in a number of breast cancer derived cell lines in comparison to normal breast epithelial cells.

Reportable Outcomes

Manuscript:

Pati, D., Zhang, N., and Plon, S.E. Linking Sister Chromatid Cohesion and Apoptosis: Role of Rad21 (under revision for Molecular and Cellular Biology).

Abstract:

Pati, D., and Plon, S.E., Linking sister chromatid cohesion to apoptosis-Role of hRad21. Abstract book of the Cell Cycle meeting, Cold Spring Harbor Laboratory, New York, May 15-19, 2002, p153 (2002).

Employment:

A summer studentship was granted to Mr. Ulysses Burley, an undergraduate student of Morehouse College, Atlanta, GA by the SMART program of Baylor College of Medicine to work on this project. SMART program is funded by the National Institute of Health, National Institute of General Medical sciences. An abstract of his summer research is included in appendix 3.

Conclusion

In summary, in contrast to previously described functions of Rad21, in chromosome segregation and DNA repair, cleavage of the cohesion protein and translocation of the C-terminal cleavage product to the cytoplasm are early events in the apoptotic pathway that amplify the apoptotic signal in a positive feed back manner by activating more caspases. Our ongoing studies in coming years will identify the physiologic role of hRad21 in the apoptotic response in normal and malignant cells. These results provide the framework for establishing a link between sister chromatid cohesion, the apoptotic response and the development of aneuploidy, all of which have not previously been tested in any model system. It is apparent that cohesin Rad21 may act as an interface between cohesion and cell death, and its cleavage may signal subsequent events of apoptosis.

References

1. Allred, D.C., Clark, G.M., Randon A.K., McGuire, W.L. Immunohistochemistry on histological sections from small (50mg) samples of pulverized breast cancer. *Histotech*, **16**: 117-120 (1993).
2. Berardo, M.D., Elledge, R.M., Moor C.D., Clark, G.M., Osborn, C.K., Allred, D.C. bcl-2 and apoptosis in lymph node positive breast carcinoma. *Cancer*, **82**: 1296-1302 (1998).
3. Biggins, S., Murray, A.W. Sister chromatid cohesion in mitosis. *Current opinion in Genetics and Development*, **9**: 230-236 (1999).
4. Ciosk, R., Zachariae, W. Michaelis, C., Shevchenko, A., Mann, M., Nasmyth, K. An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast. *Cell*, **93**: 1067-1076 (1998).
5. Furth, P.A. Apoptosis and the development of breast cancer. In "Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics" (Eds. A. M. Bowcock and N. J. Towowa), Humana Press, NY, p171-180 (1999).
6. Hauf, S., I. C. Waizenegger, and J-M. Peters. 2001. Cohesin cleavage by separase required for anaphase and cytokinesis in human cells. *Science*, **293**:1320-1323.
7. Huang, D.C.S., O'Reilly, L.A. Strasser, A., Cory, S. The anti-apoptosis function of bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. *EMBO J.*, **16**: 4628-4638 (1997).
8. Hunter ,T. Oncoprotein network. *Cell*, **88**: 333-346 (1997).
9. Jacobson, M.D., Weil, M., Raff, M.C. Programmed cell death in animal development. *Cell*, **88**: 347-354 (1997).
10. Levine, A.J., p53, the cellular gatekeeper for growth and division. *Cell*, **88**: 323-331 (1997).
11. Lipponen, P. Apoptosis in breast cancer: relationship with other pathological parameters. *Endocrine Related Cancer*, **6**: 13-16 (1999).
12. Lipponen, P., Aaltomaa, S., Kosma, V-M., Syrjanen, K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. *European Journal of Pathology*, **30A**: 2068-2073 (1994).

13. Michaelis, C., Ciosk, R., Nasmyth, K. Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids. *Cell*, **91**: 35-45 (1997).
14. Minn, A.J., Boise, L.H., Thompson, C.B. Expression of Bcl-X₁ and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. *Genes Dev.*, **10**: 2621-2631 (1996).
15. Nasmyth, K., Peters, J.M., Uhlmann, F. Splitting the Chromosome: Cutting the Ties That Bind Sister Chromatids. *Science*, **288**: 1379-1385 (2000).
16. Pati, D., Meistrich, M.L., Plon, S. E. Human Cdc34 and Rad6B ubiquitin-conjugating enzyme target repressors of cyclic AMP-induced transcription for proteolysis. *Mol. Cell. Biol.*, **19**: 5001-5013 (1999).
17. Pati, D., and Plon, S.E. Cleavage of human Rad21 cohesin protein: potential role in early apoptosis. Abstract book of the Cell Cycle meeting, Cold Spring Harbor Laboratory, New York, May 17-21, 2000, p140 (2000).
18. Pati, D., Zhang, N., Plon, S.E. Linking Sister Chromatid Cohesion and Apoptosis: Role of Rad21 (under revision).
19. Schedin, P.J., Thackray, L.B., Malone, P., Fontaine, S.C., Friis, R.R. Strange, R. Programmed cell death and mammary neoplasia. *Cancer. Treat. Res.*, **83**: 3-22 (1996).
20. Schwarze, S.R., and Dowdy, S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. *Trends in Pharmacological Sciences*, **21**: 45-48 (2000).
21. Uhlmann, F., Lottspeich, F., Nasmyth, K. Sister chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1, *Nature*, **400**: 37-42 (1999).
22. Wu, J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer. *Anticancer Research*, **16**: 2233-9 (1996).

Appendix-I
Statement of Work
(Work accomplished)

Technical Objective 1:

Month	Task	Status
1-4	Assesment of hRad21 cleavage and its immunolocalization in breast cancer cells after induction of apoptosis with DNA-damaging, non-DNA-damaging agents and microtubule-damaging drugs. Construction of mutant hRad21 expression constructs	Completed

Technical Objective 1A:

5-9	Development of a <i>in vitro</i> cleavage assay for hRad21 and <i>in vivo</i> assay for caspase activity and caspase inhibitor studies	Completed
6-10	Mapping of the Rad21 cleavage site	Completed

Technical Objective 1B:

9-12	Construction of pTAT-hRad21 and pTAT-cleaved hRad21 expression plasmids. Expression and isolation of recombinant Tat-Rad21 fusion protein	In Progress
13-18	Tansduction of TAT-hRad21 into mammary cells Cell cycle analysis, aneuploidy status and apoptosis assay of transduced cells	Not Started

Technical Objective 2A & 2B:

Month	Task
10-16	Southern blot analysis of <i>hRAD21</i> gene in breast cancer cell lines Will start soon

Technical Objective 2C & 2D:

Month	Task
1-4	Isolation of RNA, DNA and protein from breast tumor samples Completed
5-12	Immunohistochemical localization and detection of Rad21in human breast tumor sections In progress
8-18	Northern and Western analysis of hRad21 transcripts and protein expression in breast tumor specimens Start soon

Appendix -II

Submitted to MCB on May 8, 2002

Under Revision

Linking Sister Chromatid Cohesion and Apoptosis: Role of Rad21

Debananda Pati*, Nenggang Zhang, and Sharon E. Plon

Texas Children's Cancer Center, Department of Pediatrics, Baylor College of
Medicine, Houston, TX 77030, USA

Running title: Cohesin Rad21 and apoptosis

All correspondence should be addressed to:

Debananda Pati, Ph.D.

Texas Children's Cancer Center

Baylor College of Medicine

6621 Fannin St., MC 3-3320

Houston, TX 77030, USA

Tel: 832-824-4575; Fax: 832-825-4202

E-Mail: pati@bcm.tmc.edu

Word count for the Materials and Methods Section: 1,854

Word count for the Introduction, Results and Discussion section: 3,395

ABSTRACT

Rad21 is one of the major cohesin subunits that holds sister chromatids together until anaphase, when proteolytic cleavage by separase, a caspase-like enzyme, allows chromosomal separation. We show that cleavage of human Rad21 (hRad21) also occurs during apoptosis induced by diverse stimuli. Induction of apoptosis in multiple human cell lines results in the early (4 hours post insult) generation of 64 kDa and 60 kDa carboxy terminal hRad21 cleavage products. We biochemically mapped a apoptotic cleavage site at residue Asp (D)²⁷⁹ of hRad21. This apoptotic cleavage site is distinct from mitotic cleavage sites previously described. Although hRad21 is cleaved *in vitro* at D²⁷⁹ by caspase-3 and -7, indirect evidence suggests involvement of a novel caspase or caspase-like molecule in hRad21 cleavage. hRad21 is a nuclear protein, however, the cleaved 64 kDa carboxy-terminal product is translocated to the cytoplasm early in apoptosis before chromatin condensation and nuclear fragmentation. Overexpression of the 64 kDa cleavage product results in apoptosis in Molt4 and MCF-7 cells. Given the role of hRad21 in chromosome cohesion, the cleaved C-terminal product and its translocation to the cytoplasm may act as a nuclear signal for apoptosis. In summary, we show that cleavage of a cohesion protein and translocation of the C-terminal cleavage product to the cytoplasm are early events in the apoptotic pathway and cause amplification of the cell death signal in a positive feed back manner by activation of more caspases.

INTRODUCTION

Normal development and homeostasis require the orderly regulation of both cell proliferation and cell survival. Cell cycle progression and control of apoptosis are thought to be intimately linked processes. Activation of the cell cycle plays a significant role in the regulation of apoptosis (16); in some cell types and under certain conditions, apoptosis has been shown to occur only at specific stages of the cell cycle (24). Mitosis and apoptosis are also closely interrelated (25), and the mitotic index is the most important determinant of the apoptotic index (25). Although proteins that regulate apoptosis have been implicated in restraining cell cycle entry (14) and controlling ploidy (29), the effector molecules at the interface between cell proliferation and cell survival have remained elusive.

Studies in yeast and higher eukaryotes including humans have indicated that an evolutionarily conserved protein complex, called cohesin, and its subunit Mcd1/Sccl/hRad21 are required for appropriate arrangement of chromosomes during normal cell division (11, 28, for review see 20, 30, 31, 36). Analyses of Rad21 function in fission yeast, *S. pombe*, and Sccl/Mcd1 function in budding yeast, *S. cerevisiae*, demonstrate that the nuclear phosphoprotein is required for appropriate chromosomal cohesion during the mitotic cell cycle and double strand break repair after DNA damage (2, 30). Biochemical analysis of cohesin indicates that it acts as a molecular glue, and human cohesin can promote intermolecular DNA catenation, a mechanism that links two sister chromatids together (26). In budding yeast, loss of cohesion at the metaphase-anaphase transition is accompanied by proteolytic cleavage of the Sccl/Mcd1 protein (11, 28, 30, 37) followed by its dissociation from the chromatids (28, 30). Cleavage depends on a CD clan endopeptidase, Esp1 (also known as separin/separase) (37, 38), which is complexed with its inhibitor Pds1 (securin) before anaphase (23, 39). In metaphase, ubiquitin-mediated degradation of the securin protein by APC/C-Cdc20 ubiquitin-ligase releases separin protein, which proteolytically cleaves cohesin Rad21, thereby releasing the sister chromatids (7, 8, 10, 18, 42). In budding yeast, fission yeast, and human cells, Rad21 has two mitotic cleavage sites for separase (12, 37, 38), and cleavage by separase appears to be essential for sister chromatid separation and for the completion of cytokinesis (12). In contrast to the simultaneous release of cohesin from the chromosome arms and centomere region in budding yeast by separase cleavage, in metazoans, most cohesin is removed in early prophase from chromosome arms by a cleavage-independent mechanism (12, 39, 40). Only residual amounts of cohesin are cleaved at the onset of anaphase, coinciding with its disappearance from centromeres. Thus, Sccl/Mcd1/Rad21 plays a critical role in the eukaryotic cell division cycle by regulating sister chromatid cohesion and separation at the metaphase to anaphase transition.

Our results indicate that in addition to establishing and maintaining sister chromatid cohesion during mitosis, hRad21 plays a role in apoptosis, and its cleavage during apoptosis may act as a nuclear signal to initiate cytoplasmic events involved in the apoptotic pathway.

MATERIALS AND METHODS

Plasmids: Full length *hRAD21* cDNA plasmid (KIAA 0078) in pBluescript SK+ vector was obtained from Kazusa DNA Research Institute, Chiba, Japan. Full length *hRAD21* cDNA was subcloned into several mammalian expression plasmids including pFLAGCMV2, pCS2MT and pCDNA6Myc-HisC to produce epitope-tagged proteins where applicable. The following plasmids were used for transfection: pCS2MT-*hRAD21* was constructed by ligation of the 2331 bp NcoI/DraI fragment bearing the *hRAD21* cDNA, in frame to the end of the 6th myc epitope in pCS2MT (B. Kelley, Fred Hutchinson Cancer Center, Seattle, WA). pFLAGCMV2-*hRAD21* was generated by cloning the full length *hRAD21* gene contained on a 2578 bp MScI/StuI fragment from pSKKIAA0078 into pFLAGCMV2 (Kodak) that was digested with SmaI.

Site-directed mutagenesis of hRad21: pcS2MT-*hRAD21* apoptotic cleavage site (ACS) mutant-I (PDSPD²⁷⁹S to PDSPA²⁷⁹S) and mutant-II (PD²⁷⁶S²⁷⁷PD²⁷⁹S²⁸⁰ to PA²⁷⁶A²⁷⁷PA²⁷⁹A²⁸⁰) were generated using a PCR based site-directed mutagenesis protocol as previously described (33). The PCR reaction resulted in a 550 bp internal *hRAD21* fragment containing the mutations. A 221 bp piece of wild type (WT) *hRAD21* (from BsgI to PFLFI sites) was replaced with the comparable mutated fragment. The resulting plasmids, pCS2MT-*hRAD21*-ACS mut-I and pCS2MT-*hRAD21*-ACS mut-II were verified by DNA sequencing. The amino terminal (N-hRad21, encoding amino acids 1-279) and carboxy terminal (C-hRad21, encoding amino acids 280-631) cleavage products were cloned into myc epitope-tagged pCS2MT vectors using PCR amplification of the fragments from the *hRAD21* cDNA. These constructs were also verified by DNA sequencing.

Generation of hRad21 polyclonal and monoclonal antibodies: Rabbit polyclonal antibody (pAb) were raised commercially (Covance, PA) against synthetic peptides corresponding to the 14 carboxy terminal amino acid sequences of hRad21 (SDIATPGPRFHII). Immunization and affinity purification of antibodies were performed per manufacturer's protocol. Monoclonal antibody (mAb) against a partial recombinant hRad21 protein (240 AA- 631AA) was also raised commercially from IMGENEX (San Diego, CA). Both antibodies had very high titer by ELISA testing. Both antibodies recognized the WT hRad21 protein as a specific 122 kDa band in Western blot analysis and immunoprecipitated endogenous hRad21 effectively from various human and rodent cell lines and tissue lysates. Immunodetection of the 122 kDa band was blocked competitively by pretreating the lysates with recombinant hRad21 protein or synthetic C-terminal peptides. Both antibodies were also effective in immunohistochemistry and immunofluorescence staining to both paraffin embedded and tissue culture slides.

Antisera: The vendors for the following monoclonal antisera were as follows: human PARP (PharMingen, San Diego, CA), Flag epitope and mouse β -actin (Sigma), c-myc epitope (9E10), bacterial trpE, caspase-3 and caspase-7 (Oncogene Research Product,

Cambridge, MA). hRad21 N-terminal antibody was a gift from J-M. Peters (Research Institute of Molecular Pathology, Vienna, Austria).

Cell Cultures and Transfection: MCF-7 breast carcinoma cells, human choriocarcinoma JEG3 cells, and IMR90 primary lung fibroblast cells were obtained from American Type Culture Collection (ATCC) and were maintained per ATCC protocol. Human Molt4 and Jurkat T-leukemia cells (both obtained from ATCC) were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and maintained at 37 °C, 95% humidity and 5% CO₂. EL-12 mouse mammary epithelial cells were obtained from the Medina Laboratory (Baylor College of Medicine) and maintained as previously described (27). Cells were transfected with appropriate plasmids in 100 mm dishes using Superfect or Effectene reagents from Qiagen (Valencia, CA) per manufacturer's protocol. A fixed amount of plasmid DNA was used in any given experiment. The total amount of expression vector DNA was equalized by adding blank vectors to control for promoter competition effects. When necessary, transfection efficiency was monitored by use of 1 µg pDS-Red plasmid (Clontech, Palo Alto, CA) per transfection. Transfection efficiency was determined by counting percentage of red fluorescent cells in five random fields under a microscope using appropriate fluorescent channels.

Drug Treatments: Etoposide (VP-16) (20 mg/ml injections) and camptothecin were purchased from GensiaSicor Pharmaceuticals (Irvine, CA) and Sigma (St. Louis, MO), respectively. Camptothecin was dissolved in dimethyl sulfoxide (DMSO) and stored in aliquots at -20°C. Cells were plated at a concentration of 6x10⁶ cells/ml and treated with appropriate concentration of drugs. Molt4 cells were treated with etoposide while Jurkat cells were treated with camptothecin for 8h unless otherwise indicated. Controls were treated with equivalent dosages of vehicle. The caspase inhibitor z-VAD-FMK was also dissolved in DMSO and stored at -20°C. Peptide aldehydes MG115 and MG132 were obtained from Peptide Institute, Inc. (Lexington, KY) and dissolved at 10 mM in DMSO. Cells were treated with 0.025 mM proteasome inhibitors for 8h before harvesting. 15-deoxy-delta 12, 14-prostaglandin J₂ (15dPGJ₂) was purchased from Cayman Chemical Co. (Ann Arbor, MI). Induction of apoptosis in JEG3 cells using 15dPGJ₂ was carried out as described (19).

Protein Analysis and Immunoprecipitation: Cells were pelleted by low speed centrifugations (800xg for 5 min) and lysed in RIPA buffer (phosphate-buffered saline [PBS], 1% Nonidet P-40, 0.1% sodium dodecyl sulfate [SDS], 0.5% sodium deoxycholate) or PBSTDS buffer (PBS, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate) containing protease and phosphatase inhibitors (1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 1 µg pepstatin per ml, 30 µl aprotinin per ml, 0.5 µg leupeptin per ml, and 100 mM sodium orthovanadate and 100 mM sodium fluoride) (all from SIGMA) for 10-15 min on ice, followed by passage through a 21G needle. When appropriate, additional phosphatase inhibitors cocktail I and II (Sigma) were added to the lysis buffer at a dilution of 1:100. Lysates were then centrifuged at 1000xg for 20 min, and the supernatants were aliquoted and frozen at -80°C until use. Protein samples were also made from the cytoplasmic and nuclear fractions of apoptosis-induced Molt4 cells

using protocols previously described (6). After protein quantification (using BioRad's detergent compatible protein dye and BSA as standards) and normalization, 10-40 µg of protein extracts were electrophoresed on SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA). The filters were initially blocked with 5% nonfat-dry milk in TBST (Tris buffer saline containing 0.1% Tween 20) for 1-2h at room temperature and then probed with 1:1000 hRad21 mAb or hRad21 pAb, 1.5 µg/ml myc, 2.5 µg/ml Flag, 1:100,000 β-Actin, 1:2000 PARP antisera. The bound antibodies were visualized by the enhanced chemiluminescence (ECL) detection system (Amersham, Buckinghamshire, England), in combination with the HRP-conjugated anti-mouse or anti-rabbit secondary antibodies as appropriate, and intensity of the specific bands in the exposed films was quantified. In some of the later studies, bound primary antibodies were detected with IRD800 dye-labeled appropriate species-specific secondary antisera and signal was visualized on a Li-Cor (Lincoln, NE) Odyssey infrared scanner. Immunoprecipitation was performed as follows: 1.0 ml of cell lysate was pre-cleared by incubation with 10 µl of normal mouse IgG and 20 µl protein G plus agarose (Oncogene Research Product, Cambridge, MA) at 4°C for 1h on a rotator. The pre-cleared-lysate was collected after centrifugation at 800xg for 15 min. 0.5-1.0 ml of pre-cleared lysate normalized for protein concentrations was incubated at 4°C for 1h with primary antibodies followed by addition of 20 µl Protein A/G plus agarose. The mix was then incubated at 4°C for another 12-16h on a rotator. Precipitates were then washed four times with 1ml of ice-cold PBS with a final wash in the lysis buffer before electrophoresis and Western blot analysis.

Mapping of hRad21 apoptotic cleavage sites: Apoptosis was induced in Molt4 T-cells by treating with 10 µM etoposide for 8h. Protein lysates were subjected to immunoprecipitation using hRad21 mAb or a control bacterial trpE mAb. The immunoprecipitated samples were run on 6% SDS PAGE gels that included 0.1 mM sodium thioglycolate (Sigma) as a scavenger in the upper running buffer. Electrophoresed samples were then electroblotted onto PVDF membranes at room temperature (~25°C) using CAPS buffer (10mM CAPS, 10% methanol, pH 11) at 400 mAmps for 45 min. At the end of the transfer, the blotted membranes were rinsed with water for 2-5 min, stained with 0.05% Coomassie blue in 1% acetic acid, 50% methanol for 5-7 min, destained in 50% methanol until the background was pale blue (5-15 min), and finally rinsed with water for 5-10 min. Appropriate bands were cut out and air-dried and sent for N-terminal sequencing by the protein chemistry core laboratory at Baylor College of Medicine.

Immunocytochemistry, DAPI staining of nuclei and detection of apoptosis: EL-12 cells were grown on FALCON culture slides. Medium was poured off before cells were treated with 0, 50, 100, 200 J/m² of UV. Fresh medium was added immediately after UV radiation. Cells were fixed with cold methanol after 6 h of UV treatment (unless otherwise noted). Double staining of hRad21 was performed by incubating anti-hRad21 mAb and rabbit anti C-terminal hRad21 pAb. The signals of mAb and pAb were visualized by adding rhodamine-labeled goat anti-mouse IgG (1:100) and fluorescein-labeled goat anti-rabbit IgG (1:800) (Molecular Probes), respectively. Slides were

mounted with Vectashield mounting media with DAPI (Vector, H-1200) and sealed with nail makeup. Images were obtained with a Zeiss inverted fluorescent microscope coupled to an Axiocam hi-resolution digital camera operated by Axiovision 3.0 software (Carl Zeiss Inc., Thornwood, NY).

For detection of apoptosis in transiently transfected MCF-7 cells with hRad21 plasmids, the cells were first washed twice with ice-cold PBS and then fixed with cold methanol for 10 min. The fixed cells were washed again with PBS and mounted with Vectashield mounting media with DAPI (Vector, H-1200). At least 50 fluorescent nuclei from each treatment group were screened and counted for normal morphology (rounded chromatin) or for apoptotic nuclei (fragmented and condensed chromatin). Data were expressed as percentage of apoptotic cells out of total counted cells.

The caspase-3 activities in Molt4 cells were measured using a caspase-3 assay kit from Clontech (Palo Alto, CA) per manufacturer's protocol.

Proteolytic cleavage assay of the *in vitro* transcribed/translated hRad21: ³⁵S-hRad21 or unlabeled (non-isotopic) hRad21 was produced by *in vitro* transcription/translation using the TnT rabbit reticulocyte lysate system (Promega, WI, USA). Rabbit reticulocyte lysate was combined with 1 µg of plasmid DNA containing either the WT *hRAD21* cDNA (pCS2MT-*hRAD21*) or *hRAD21* apoptotic cleavage site (ACS) mutants, ACS-mut-I or ACS-mut-II and SP6 RNA polymerase. Reaction in the absence of plasmid DNA served as a negative control. Reactions were incubated at 30°C for 90 min. *In vitro* cleavage reaction was performed as previously described (9). In brief, 6 µl of *in vitro* translated ³⁵S-hRad21 (WT) or the ACS-mut-I or ACS-mut-II mutants were combined with 30 µl of reaction buffer (20 mM HEPES pH 7.4, 2 mM DTT, and 10% glycerol) and one of the following enzyme sources: 2 µl (200U) recombinant caspase-3, or 2 µl (4U) caspase-7 or 2 µl (10 µg) Molt4 cell lysates (treated with DMSO or 10 µM etoposide for 6h). The cleavage reaction was performed at 37°C for 1h, after which 8 µl 6X sample buffer with DTT was added to stop the reaction. 20 µl of this reaction was electrophoresed on 6% SDS PAGE gels, fixed with methanol and acetic acid for 30 min, dried on a gel dryer and exposed to a STORM imager. Bands were quantified using the ImageQuant 5.2 software (Molecular Dynamics, Inc., Sunnyvale, CA). Unlabeled (non-isotopic) hRad21 from TnT reactions was also incubated in a similar manner as described above in the presence or absence of caspase-3 or caspase-7. Samples were then analyzed by SDS-PAGE followed by Western blotting with hRad21 antisera.

RESULTS

We report the role of hRad21 in the apoptotic response and cleavage of the hRad21 protein in human cells by a caspase-like activity.

Cleavage of hRad21 during apoptosis: While examining the expression of Rad21 in mammalian cells after DNA damage, we surprisingly identified cleavage of hRad21 protein after induction of apoptosis. hRad21 was cleaved during etoposide-induced apoptosis in human Molt4 T-cell leukemia. Induction of apoptosis resulted in the generation of approximately 64 kDa and 60 kDa cleavage products determined by a monoclonal hRad21 antibody (Fig. 1). The cleavage of hRad21 in Molt4 cells was a function of etoposide dose (Fig. 1A) as the ratio of cleaved hRad21 to full length protein appeared directly proportional to increasing doses of etoposide over the tested range (10-50 μ M). hRad21 cleavage products were also detected in a number of other cell lines following induction of apoptosis either by DNA-damaging agents (ionizing radiation and topoisomerase inhibitors) (data not shown) and/or non-DNA-damaging agents (prostaglandin (Fig. 1B), proteasome inhibitor (Fig. 1C), cycloheximide treatment, and cytokine withdrawal, data not shown). In addition, equivalent doses of ionizing radiation in cells that are resistant to apoptosis (Raji lymphoid leukemia and H1299 large cell lung carcinoma) did not generate this band (data not shown); thus, it was not a simple by-product of DNA damage.

Translocation of the carboxy-terminal hRad21 fragment to the cytoplasm after induction of apoptosis: Molt4 cells were treated with 10 μ M etoposide for 0, 1, 2, 3, 4, 6 and 12h. Induction of apoptosis was verified by determining caspase-3 activity (Fig. 2A) and the cleavage of PARP protein (data not shown). Western blot analysis of cytoplasmic and nuclear fractions using a C-terminal hRad21 antibody detected a 122 kDa protein band in the non-induced cells (0 h), and as reported before, full length hRad21 is found to be exclusively in the nuclear fractions (Fig. 2B). However, induction of apoptosis resulted in the early (4h post induction) generation of approximately 64 kDa and 60 kDa cleavage products as determined by a C-terminal hRad21 antibody (Fig. 2B). At the end of 12h post induction, hRad21 protein is almost cleaved. Although hRad21 is a nuclear protein, the cleaved products are found in both nuclear and cytoplasmic fractions after induction of apoptosis (Fig. 2B). The identities of these two cleavage products were investigated using an N-terminal hRad21 antibody. As expected, the N-terminal antibody could not detect the 64 kDa and 60 kDa cleavage products either in the cytoplasmic or nuclear fractions. In contrast, this antibody detected two other bands (approximately 50 kDa and 55 kDa) only in the nuclear fractions (data not shown). These results indicated that hRad21 may potentially be cleaved at two different sites following induction of apoptosis. The C-terminal hRad21 cleavage products but not the N-terminal hRad21 products translocate to the cytoplasm after cleavage following induction of apoptosis.

The identities of the cleavage products were confirmed through recognition by monoclonal antibodies to hRad21 in immunoprecipitation (IP) and Western blot analyses (Fig. 3). Monoclonal hRad21 antibody selectively immunoprecipitated both the 60 kDa and 64 kDa hRad21 cleavage products, along with the native 122 kDa full length hRad21

protein in etoposide-induced Molt4 cells. Cells treated with vehicle only and control IP with isotype bacterial TrpE antibody did not detect hRad21 cleavage products, confirming the identities of the cleaved bands as hRad21 products. Both monoclonal and polyclonal C-terminal antibodies detected both the 64 kDa and 60 kDa bands, confirming these bands as the C-terminal portion of the cleaved protein.

Translocation of hRad21 was further investigated in EL-12 mammary epithelial cells by immunofluorescent staining using the monoclonal and the C-terminal hRad21 polyclonal antisera. Unlike Molt4 cells, EL-12 cells have a large cytoplasm to facilitate visualization. In these cells, Rad21 was entirely nuclear (Fig. 4, middle panel). Apoptosis was induced by treating EL-12 cells with UV light (100J/m^2) and was verified by the cleavage of Rad21 and PARP protein (data not shown). Immunofluorescent staining of the UV-treated cells by the C-terminal antibody clearly demonstrated translocation of the cleaved C-terminal Rad21 to the cytoplasm (Fig. 4, bottom panel).

Inhibition of hRad21 cleavage by caspase peptide inhibitors: Peptide-based caspase inhibitors abrogated the apoptosis-induced cleavage of hRad21, suggesting the involvement of caspases in hRad21 cleavage (Fig. 5). Molt4 cells were treated with $20\text{ }\mu\text{M}$ z-VAD-FMK, a broad spectrum caspase inhibitor one hour prior to etoposide ($10\text{ }\mu\text{M}$) treatment. As shown in Fig. 5, treatment with z-VAD-FMK completely blocked etoposide-induced hRad21 cleavage. In an *in vitro* cleavage assay described later, z-VAD-FMK also inhibited caspase-3 induced cleavage of ^{35}S -hRad21 (data not shown).

Identification of the apoptotic cleavage site in hRad21: The hRad21 cleavage site was mapped through N-terminal sequencing of Coomassie-stained PVDF membranes that were electroblotted with immunoprecipitated hRad21 cleavage products (Fig. 6). Sequencing of the 64 kDa band revealed that hRad21 was cleaved at Asp (D)²⁷⁹. The sequence obtained was SVDPVEP. The immediate sequence N-terminal to the cleavage site was PDSPD²⁷⁹. Thus there was a repeat of the sequence encompassing the cleavage site, i.e., PDSPD²⁷⁹/SVDPVEP (Fig. 6A). We were not successful in sequencing the 60 kDa band, possibly due to an N-terminal blocking effect. To verify whether specific cleavage occurred at Asp (D)²⁷⁹ in hRad21 after induction of apoptosis, we introduced a point mutation by substituting an alanine (A) for aspartate (D) at this position of hRad21(D279A) (Fig. 6B). Furthermore, because of the repetition of the cleavage sequence ²⁷⁵PDSPDS²⁸⁰, we made a second mutant by substituting alanine (A) for both aspartates (D) and serine (S) residues, i.e., hRad21 (²⁷⁵PDSPDS²⁸⁰ to ²⁷⁵PAAPAA²⁸⁰). We then transiently transfected Molt4 cells with WT or mutant hRad21 tagged with the myc epitope at the N-terminus, and treated these cells with etoposide as indicated. As shown in Fig. 6C, antibody against myc-tag (9E10) revealed the proteins encoded by the transfected hRad21 WT and hRad21 ACS mut-I and ACS mut-II constructs. However, the cleavage fragments were only detected for WT hRad21, not for both of the mutants, indicating that a point mutation at Asp (D)²⁷⁹ prevented cleavage (Fig. 6C). We reprobbed the blot with anti-hRad21 monoclonal Ab and found that both the 60 kDa and 64 kDa C-terminal fragments were present in all etoposide treated cells (data not shown), confirming that endogenous hRad21 was cleaved in cells transfected with hRad21 mutants.

Involvement of caspases in hRad21 cleavage: Closer inspection of the adjoining sequence at the Rad21 apoptotic cleavage site (D²⁷⁹SVD) (Fig. 6A) revealed a putative recognition sequence for a primitive caspase Ced3. This sequence is conserved in vertebrates including human, mouse and frog (*Xenopus*). The sequence of the putative cleavage site, together with the inhibitory effect of a panel of caspase inhibitors on etoposide-induced apoptosis in Molt4 cells indicated the possible involvement of a caspase family protease. While the experiments with caspase inhibitors suggested involvement of a caspase family of protease(s) in the pathway leading to hRad21 cleavage, they did not however demonstrate direct internal cleavage of hRad21 by a caspase. We therefore, utilized an *in vitro* cleavage assay as described previously for the retinoblastoma protein (Rb) (9) to examine the ability of purified caspase to cleave hRad21 (Fig. 7). We used two caspases, caspase-3 and caspase-7 that are major regulators of apoptosis in diverse cell types (35) (Fig. 7A), along with lysates from Molt4 cells treated with etoposide (apoptotic lysate) or vehicle (non-apoptotic lysate) to examine their role in hRad21 cleavage (Fig. 7B). Together, caspase-3 and caspase-7 comprise the caspase-3 subfamily and both enzymes recognize and cleave after the consensus cleavage site DXXD (1). Addition of recombinant caspase-3 or caspase-7 to the *in vitro* transcribed and translated hRad21 in rabbit reticulocyte lysates clearly resulted in the production of a 64 kDa hRad21 fragment (Fig 7A, B). The 64 kDa fragment produced by these caspases precisely co-migrated with the 64 kDa band produce by apoptotic Molt4 lysates while the control (non-apoptotic) cell lysate could not cleave hRad21 protein. On the other hand, both the hRad21 ACS mutants failed to be cleaved by these two caspases or by apoptotic cell lysates in this assay, strongly suggesting that caspase-3 or caspase-7-like enzymes in the apoptotic cells or extracts were responsible for cleavage at the putative caspase recognition site D²⁷⁹ of hRad21.

In addition to the 64 kDa fragment, several other fragments were generated by caspase-3 and -7. It is possible that the 64 kDa fragment was degraded further by these caspases and resulted in the production of smaller fragments. In the presence of caspase-7 but not caspase-3, a 95 kDa fragment of hRad21 was also generated, suggesting another caspase site N-terminal to the D²⁷⁹ cleavage site. In the *in vitro* cleavage assay caspase-3 and -7 failed to generate the 60 kDa hRad21 fragment that accompanies the 64 kDa fragment after induction of apoptosis, suggesting that the cleavage site generating the 60 kDa fragment was not recognized by caspase-3 and -7.

To determine whether caspase-3 is essential for the *in vivo* cleavage of hRad21, we utilized a caspase-3 deficient MCF-7 breast cancer cell line (21). In experiments using etoposide or tamoxifen-induced apoptosis in MCF-7 cells, hRad21 cleavage products were detected, indicating that caspase-3 was not essential for hRad21 cleavage (Fig. 8) and a caspase other than caspase-3 can act upon hRad21 to result in cleavage following induction of apoptosis.

hRad21 C-terminal cleavage product promotes apoptosis: A possible role for hRad21 in inducing apoptosis was first seen in preliminary experiments in which overexpression of hRad21 in Molt4 cells resulted in apoptotic phenotypes and enhanced expression of caspase-3 levels. As seen in Fig. 9, hRad21 overexpression from a CMV promoter–

driven myc-tagged plasmid resulted in a 5-7 fold increase in caspase-3 activity compared to empty vector control. However, conclusive evidence for the role of cleaved hRad21 in promoting apoptosis was found in transiently transfected Molt4 cells with mammalian expression plasmids encoding the full length hRad21 or cDNAs encoding the two cleavage products, hRad21 N-terminal (aa 1-279) or hRad21 C-terminal (aa 280-631) proteins (Fig. 9). Although overexpression of WT hRad21 induced moderate levels of apoptosis as determined by caspase-3 activity in Molt4 cells, overexpression of hRad21 C-terminal cleavage product but not the N-terminal hRad21 cleavage product dramatically increased the caspase-3 activity in Molt4 cells (Fig. 9). The transfection efficiency in Molt4 was 35%, determined by a co-transfection with a red fluorescent plasmid pDSRed. Similar results were also obtained in hRad21 WT, hRad21 C-terminal and hRad21 N-terminal transfected MCF-7 cells. In these cells apoptosis was determined by monitoring the phenotype of the DAPI stained nuclei. 40% of transfected cells had cellular and nuclear phenotypes typical of apoptosis, such as a round appearance with shrunken cell volume, chromatin condensation and nuclear disintegration (data not shown). These findings clearly demonstrated that the C-terminal hRad21 cleavage product was pro-apoptotic as determined by increased caspase-3 activity and apoptotic morphology and that its translocation to the cytoplasm may play a role in promoting apoptosis.

Apoptotic cleavage of hRad21 is not affected by the status of the p53 tumor suppressor protein in the cell: In view of the pivotal role of the p53 gene product in regulation of cell cycle and apoptosis, we examined the role of p53 in the apoptotic cleavage of hRad21. We used two myeloid leukemia cell lines ML-1 and HL-60 with WT and null p53 genotypes, respectively (32, 41). Apoptosis was induced using UV (20J/m^2) and ionizing radiation (20 Gy) in these cells. As shown in Fig. 10, in both the cell lines, induction of apoptosis resulted in the cleavage of hRad21 protein, indicating lack of a role for p53 in hRad21 cleavage.

DISCUSSION

Sister chromatid cohesion during DNA replication plays a pivotal role in accurate chromosomal segregation in the eukaryotic cell cycle. Rad21 is one of the major cohesin subunits that keeps sister chromatids together until anaphase when proteolytic cleavage by separase allows the chromosomes to separate. Mitotic cleavage sites in Rad21 in yeast as well as humans have been mapped (12, 37, 39). Here we show that hRad21 cleavage occurs during apoptosis and is induced by various agents including DNA damaging (ionizing radiation and topoisomerase inhibitors) as well as non-DNA damaging agents (cycloheximide treatment, cytokine withdrawal and treatment with proteasome inhibitors). We have biochemically mapped the apoptotic cleavage site in human Rad21 to PDSPD²⁷⁹/S which is distinct from that of the mitotic cleavage sites (DREIMR¹⁷²/E and IEEPSR⁴⁵⁰/L) previously described (12). The apoptotic cleavage site is conserved among vertebrate species, and it is likely that cleavage is mediated by a nuclear caspase or caspase-like molecule, as this cleavage site bears the characteristic caspase-3 subfamily recognition motif (DXXD) and hRad21 is cleaved *in vitro* by the two major apoptosis executioner caspases, caspase-3 and caspase-7. hRad21 cleavage is not restricted to transformed cancer cells, as induction of apoptosis also resulted in hRad21 cleavage in a primary cell line IMR90 (data not shown) as well as a non-transformed immortal cell line EL-12.

Cleavage of hRad21 appears to be an early event in the apoptotic pathway. The immunofluorescence experiments clearly demonstrate the translocation of the hRad21 C-terminal cleavage products to the cytoplasm early (3-4h post insult) in apoptosis. Early cleavage of hRad21 and its translocation to the cytoplasm after induction of apoptosis and before the characteristic nuclear condensation and DNA fragmentation begin may have an important functional role in promoting and/or accelerating the apoptotic process. Indeed, our results clearly demonstrate that hRad21 proteolysis by a caspase family protease at D²⁷⁹/S leads to the production of a pro-apoptotic C-terminal cleavage product. Translocation of this 64 kDa hRad21 cleavage product to the cytoplasm early in apoptosis may act as a nuclear signal that promotes and accelerates subsequent events of apoptosis. The specificity of this product was further determined as the N-terminal hRad21 cleavage product neither translocates nor has the ability to induce apoptosis. We have not explored the role of the 60 kDa hRad21 product generated at a cleavage site other than D²⁷⁹/S, in the apoptotic process.

The physiological significance of cohesin hRad21 cleavage in apoptosis is intriguing. The nuclear signal (s) that detects subsequent events of apoptosis in the cytoplasm and mitochondria have remained elusive. It is possible that cleavage of hRad21 at the onset of apoptosis and the translocation of the C-terminal cleavage product to the cytoplasm acts as cues to accelerate the apoptotic process. We have previously identified a number of cytoplasmic proteins involved in the apoptotic pathway as interactors of the hRad21 protein in a yeast two-hybrid assay not described in the present study (Pati D, Plon SE, unpublished). These findings further strengthen the notion that the translocated C-terminal hRad21 protein plays a functional role in apoptosis.

Caspase-mediated proteolysis of hRad21 and the partial removal of hRad21 from the nucleus may expose the chromosomal DNA to DNase and other proteins responsible for chromatin condensation and apoptotic DNA fragmentation. This simple scenario is less likely, as overexpression of the hRad21 ACS mutants, mut-I and mut-II did not prevent etoposide and tamoxifen-induced apoptosis and nuclear fragmentation in MCF-7 cells (data not shown). hRad21 was originally isolated in fission yeast as an essential protein with a role in DNA double strand break repair induced by ionizing radiation (3). It is therefore logical to think that disruption of the DNA repair function of hRad21 may be necessary during the execution of apoptosis. This notion has been strengthened with recent findings that a number of DNA repair enzymes such as Rad51 (15), ATM (13), DNA-PK (5), PARP (22) and cell cycle regulators such as Rb (9) are cleaved by caspases. Coordinated destruction of the DNA repair machinery and cell cycle regulators by the caspase family of proteases therefore constitutes a physiologically relevant process that promotes and accelerates chromosomal condensation and DNA fragmentation without interference by the cell cycle and DNA repair machinery. Unlike hRad21, however, cleavage products of these other DNA repair proteins have not been reported to play a direct role in promoting apoptosis. In this case, cleavage of hRad21 by caspases may play a unique role in amplifying the apoptotic signal by elevating the level of caspase activity (Fig. 11). A similar mechanism for amplifying the apoptotic signal for caspase substrate vimentin has recently been described (4).

The p53 tumor suppressor protein plays a central role in the regulation of the cell cycle and apoptosis after DNA damage (17, 34). In the event that DNA damage is more severe and non-repairable, p53 directs the cells into apoptosis through the Bax/Bcl-2 pathway. p53 status does not appear to have any effect on the apoptotic cleavage of hRad21 after DNA damage (i.e. UV and IR), indicating the lack of involvement of the p53 pathway in hRad21 cleavage. It is possible that a parallel p53-independent pathway may regulate the genotoxic-damage induced hRad21 cleavage.

Finally, it is interesting to note that cleavage of cohesin hRad21 is carried out by a separase in mitosis and by a caspase in apoptosis at different sites in the protein. Both these proteases belong to the distantly related CD-clan protease family (38), suggesting an evolutionarily conserved mechanism shared by the mitotic and apoptotic machinery. hRad21 may serve as the link between the two key cellular processes of mitosis and apoptosis. In summary, in contrast to previously described functions of Rad21, in chromosome segregation and DNA repair, cleavage of the cohesion protein and translocation of the C-terminal cleavage product to the cytoplasm are early events in the apoptotic pathway that amplify the apoptotic signal in a positive feed back manner by activating more caspases. These results provide the framework to identify the physiologic role of hRad21 in the apoptotic response in normal and malignant cells.

ACKNOWLEDGEMENTS

We thank T. Nagase (Kazusa DNA Research Institute, Chiba, Japan) for KIAA0078 (SK-hRad21) plasmid, J-M. Peters (Research Institute of Molecular Pathology, Vienna, Austria) for Rad21 N-terminal polyclonal antibody and D. Medina (Baylor College of Medicine) for EL-12 cell line. We thank Lisa Wang for critically reading the manuscript and Sara Ekhlassi for technical assistance.

This study was supported by grants from the U.S. Army Medical Research and Materiel Command (DAMD-17-00-1-0606, DAMD-01-1-0142 and DAMD 01-1-0143 to DP) and (DAMD-17-97-1-7284 and DAMD-17-98-1-8281 to SEP).

REFERENCES

1. Alnemri, E., S. D. J. Livingston, D. W. Nicholson, G. Salvesen, N. A. Thornberry, W. W. Wong, and J. Yuan. 1996. Human ICE/CED-3 protease nomenclature. *Cell* **87**:171.
2. Biggins, S., and A. W. Murray. 1999. Sister chromatid cohesion in mitosis. *Curr. Opin. Genet. Dev.* **9**:230-236.
3. Birkenbihl, R. P., and S. Subramani. 1992. Cloning and characterization of rad21 an essential gene of *Schizosaccharomyces pombe* involved in DNA double-strand-break repair. *Nucleic Acids Res.* **20**:6605-6611.
4. Byun, Y., F. Chen, R. Chang, M. Trivedi, K. J. Green, and V. L. Cryns. 2001. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. *Cell Death Differ.* **8**: 443-450.
5. Casciola-Rosen, L. A., G. J. Anhalt, and A. Rosen. 1995. DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. *J. Exp. Med.* **182**:1625-1634.
6. Chaturvedi, M. M., R. LaPushin, and B. B. Aggarwal. 1994. Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response. *J. Biol. Chem.* **269**:14575-14583.
7. Ciosk, R., W. Zachariae, C. Michaelis, A. Shevchenko, M. Mann, and K. Nasmyth. 1998. An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast. *Cell* **93**:1067-1076.
8. Cohen-Fix, O., J-M. Peters, M. W. Kirschner, and D. Koshland. 1996. Anaphase initiation in *Saccharomyces cerevisiae* is controlled by the APC-dependent degradation of the anaphase inhibitor Pds1p. *Genes Dev.* **10**:3081-93.
9. Fattman, C. L., S. M. Delach, Q. P. Dou, and D. E. Johnson. 2001. Sequential two-step cleavage of retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis. *Oncogene* **20**:2918-2926.
10. Funabiki, H., H. Yamano, K. Kumada, K. Nagao, T. Hunt, and M. Yanagida. 1996. Cut2 proteolysis required for sister-chromatid separation in fission yeast. *Nature* **381**:438-441.
11. Guacci, V., D. Koshland, and A. Strunnikov. 1997. A direct link between sister chromatid cohesion and chromosome condensation revealed through the analysis of MCD1 in *S. cerevisiae*. *Cell* **9**:47-57

12. Hauf, S., I. C. Waizenegger, and J-M. Peters. 2001. Cohesin cleavage by separase required for anaphase and cytokinesis in human cells. *Science* **293**:1320-1323.
13. Hotti, A., K. Jarvinen, P. Siivola, and E. Holtta. 2000. Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases. *Oncogene* **19**:2354-2362.
14. Huang, D. C. S., L. A. O'Reilly, A. Strasser, and S. Cory. 1997. The anti-apoptosis function of bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. *EMBO J.* **16**:4628-4638.
15. Huang, Y., S. Nakada, T. Ishiko, T. Utsugisawa, R. Datta, S. Kharbanda, K. Yoshida, R. V. Talanian, R. Weichselbaum, D. Kufe, and Z. M. Yuan. 1999. Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. *Mol. Cell Biol.* **19**:2986-2997.
16. Hunter, T. 1997. Oncoprotein network. *Cell* **88**:333-346.
17. Isreals, L. G., and E. D. Isreals. 1999. Apoptosis. *Stem Cells* **17**:306-313.
18. Jallepalli, P. V., I. C. Waizenegger, F. Bunz, S. Langer, M. R. Speicher, J-M. Peters, K. W. Kinzler, B. Vogelstein, and C. Lengauer. 2001. Securin is required for chromosomal stability in human cells. *Cell* **105**:445-457.
19. Keelan, J. A., T. A. Sato, K. W. Marvin, J. Lander, R. S. Gilmour, and M. D. Mitchell. 1999. 15-deoxy-delta 12, 14-prostaglandin J₂, a ligand for peroxisome proliferator-activated receptor-g, induces apoptosis in JEG3 choriocarcinoma cells. *Biochem. Biophys. Res. Comm.* **262**:579-585.
20. Koshland, D. E., and V. Guacci. 2000. Sister chromatid cohesion: the beginning of a long and beautiful relationship. *Curr. Opin. Cell Biol.* **12**:297-301.
21. Kurokawa, H., K. Nishio, H. Fukumoto, A. Tomonari, T. Suzuki, and N. Saijo. 1999. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. *Oncol. Rep.* **6**:33-37.
22. Lazebnik, Y. A., S. H. Kaufmann, S. Desnoyers, G. G. Poirier, and W. C. Earnshaw. 1994. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. *Nature* **371**:346-347.
23. Leismann, O., A. Herzig, S. Heidmann, and C. F. Lehner. 2000. Degradation of Drosophila PIM regulates sister chromatid separation during mitosis. *Genes. Dev.* **14**:2192-205.

24. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. *Cell* **88**:323-331.
25. Lipponen, P., S. Aaltomaa, V-M. Kosma, and K. Syrjanen. 1994. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. *Eur. J. Cancer* **30A**:2068-2073.
26. Losada, A., and T. Hirano. 2001. Shaping the metaphase chromosome: coordination of cohesion and condensation. *Bioessays* **23**:924-935.
27. Medina, D., and F. S. Kittrell. 1993. Immortalization phenotype dissociated from the preneoplastic phenotype in mouse mammary epithelial outgrowths *in vivo*. *Carcinogenesis* **14**:25-28.
28. Michaelis, C., R. Ciosk, and K. Nasmyth. 1997. Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids. *Cell* **91**:35-45.
29. Minn, A. J., L. H. Boise, and C. B. Thompson. 1996. Expression of Bcl-X_L and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. *Genes Dev.* **10**:2621-2631.
30. Nasmyth, K., J-M. Peters, and F. Uhlmann. 2000. Splitting the chromosome: cutting the ties that bind sister chromatids. *Science* **288**:1379-1385.
31. Nasmyth, K. 2001. Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis. *Annu. Rev. Genet.* **35**:673-745.
32. O'Connor, P. M., J. Jackman, I. Bae, T. G. Myers, S. Fan, M. Mutoh, D. A. Scudiero, A. Monks, E. A. Sausville, J. N. Weinstein, S. Friend, A. J. Fornace Jr., and K. W. Kohn. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. *Cancer Res.* **57**:4285-300.
33. Shimada, A. 1996. PCR-based site-directed mutagenesis. *Methods Mol. Biol.* **57**:157-165.
34. Strasser, A., L. O'Connor, and V. M. Dixit. 2000. Apoptosis Signaling. 2000. *Annu. Rev. Biochem.* **69**:217-245.
35. Thornberry, N. A., Y. Lazebnik. 1998. Caspases: enemies within. *Science* **281**:1312-1316.

36. Uhlmann, F., and K. Nasmyth. 1998. Cohesion between sister chromatids must be established during DNA replication. *Curr. Biol.* **8**:1095-1101.
37. Uhlmann, F., F. Lottspeich, and K. Nasmyth. 1999. Sister chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1. *Nature* **400**: 37-42.
38. Uhlmann, F., D. Wernic, M. A. Poupart , E. V. Koonin, and K. Nasmyth. 2000. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. *Cell* **103**: 375-386.
39. Waizenegger, I. C., S. Hauf, A. Meinke, and J-M. Peters. 2000. Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase. *Cell* **103**:399-410.
40. Warren, W. D., S. Steffensen, E. Lin, P. Coelho, M. Loupart, N. Cobbe, J. Y. Lee, M. J. McKay, T. Orr-Weaver, M. M. Heck, and C. E. Sunkel. 2000. The *Drosophila* RAD21 cohesin persists at the centromere region in mitosis. *Curr. Biol.* **10**:1463-1466.
41. Zhan, Q., S. Fan, I. Bae, C. Guillouf, D. A. Liebermann , P. M. O'Connor, and A. J. Fornace. 1994. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. *Oncogene* **9**:3743-51.
42. Zou, H, T. J. McGarry, T. Bernal, and M. W. Kirschner. 1999. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. *Science* **285**:418-22.




Fig. 1. Apoptosis-induced cleavage of hRad21 by etoposide (A), prostaglandin (B) and proteasome inhibitors (C) in Molt4 T-cell leukemia and JEG3 choriocarcinoma cells. (A). Dose-related cleavage of hRad21 in Molt4 T-cell leukemia, treated with increasing concentration of etoposide (10-50 μ M) for 6h and (B) JEG3 cells with 15-deoxy-delta 12, 14-prostaglandin J_2 (2.4-8 μ M) for 16h. (C) Molt 4 cells were also treated with 0.025 mM proteasome inhibitors, MG115 and MG132 for 8h. Lysates of these samples were resolved on a 4-20% SDS-PAGE gel, transferred to a nitrocellulose membrane and analyzed by Western blot using a monoclonal hRad21 antibody. Induction of apoptosis resulted in the generation of approximately 64 kDa and 60 kDa hRad21 cleavage products (shown by the closed arrows). Full length hRad21 (122 kDa) is shown by the open arrow.




Fig. 2. Time course of etoposide-induced hRad21 cleavage. Molt4 cells were incubated in the absence (lane 1) or presence of 10 μ M etoposide for 1, 2, 3, 4, 6 and 12 hours. At the end of the incubation period lysates from cytoplasmic and nuclear fractions were made. (A) Induction of apoptosis was verified by determining caspase-3 activity in a Western blot analysis using anti-caspase-3 monoclonal antibody. Pro-caspase-3 and the active caspase-3 are indicated. (B) Time course of cleavage of hRad21 protein in etoposide-induced cytoplasmic and nuclear fractions were examined using a C-terminal Rad21 pAb. Full length hRad21 (122 kDa, open arrow), C-terminal cleaved 60 and 64 kDa fragments (closed arrows) are indicated.




Fig. 3. Immunoprecipitation (IP) and Western blot (WB) analyses of the hRad21 cleavage products. Apoptosis was induced in Molt4 T-cells by treating with 10 μ M etoposide (etop) for 8h. Protein lysates were subjected to immunoprecipitation using hRad21 mAb or a control bacterial trpE mAb. Both monoclonal and polyclonal C-terminal antibodies detected both 64 kDa and 60 kDa bands (closed arrows), indicating these bands are from the C-terminal portion of the cleaved protein.




Fig. 4. C-terminal Rad21 cleavage product translocates to the cytoplasm after induction of apoptosis. Apoptosis was induced by treating EL-12 mammary epithelial cells with UV light (100J/m²). UV-treated (bottom panel) and untreated control (middle panel) cells were subjected to immunofluorescent staining and microscopy using a C-terminal hRad21 polyclonal antibody (pAb) (green fluorescence) and hRad21 monoclonal antibody (mAb) (red

fluorescence), respectively. The signals of mAb and pAb were visualized by adding rhodamine-labeled goat anti-mouse and fluorescein-labeled goat anti-rabbit IgG, respectively. Upper panel is the background staining (negative control) from the fluorescein-labeled secondary antibody in the present of normal mouse and rabbit IgG. The nuclear material is visualized by DAPI staining (blue fluorescence). Right hand panel is a merged image of red, blue and green fluorescence.




Fig. 5. Caspase peptide inhibitors inhibit etoposide-induced cleavage of hRad21. Molt4 cells were treated with 20 μ M z-VAD-FMK, a broad spectrum caspase inhibitor one hour prior to etoposide (10 μ M) treatment for 6 hours. At the end of the incubation period protein lysates were analyzed on a 6% SDS-PAGE gel followed by Western blot analysis using hRad21 C-terminal pAb.




Fig. 6. Characterization of the apoptotic cleavage site of hRad21. hRad21 cleavage site was mapped biochemically as described in the Methods section through N-terminal sequencing of Coomassie-stained PVDF membrane that was electroblotted with immunoprecipitated hRad21 cleavage products. (A) Comparison of the apoptotic cleavage recognition site and the adjoining sequence of hRad21 with other vertebrates (Mouse and *Xenopus*) and simpler eukaryotic Rad21 proteins. An arrow indicates the peptide bond cleaved during apoptosis. (B) Construction of the apoptotic cleavage site mutants, ACS mut-I and ACS mut-II, to verify whether specific cleavage occurs at Asp (D)²⁷⁹ in hRad21 after induction of apoptosis, by introducing a point mutation to substitute an alanine (A) for aspartate (D) (mut-I) or alanine (A) for aspartate (D) and serine (S) (mut-II). (C) Molt4 cells were transiently transfected with blank vector (pCS2MT), WT hRad21 (pCS2MT-*hRAD21*) or ACS mutants tagged with myc epitope at their N-termini (pCS2MT-ACSmut-I or pCS2MT-ACSmut-II), and treated these cells with etoposide as indicated. Lysates were analyzed on 6% SDS-PAGE followed by Western blot analysis using antibody against myc-tag (9E10) to distinguish the cleavage products from the native forms of transfected hRad21 WT and hRad21 ACS mut-I and ACS mut-II proteins.




Fig. 7. Cleavage of *in vitro* translated hRad21 by recombinant caspase-3 and caspase-7. (A) In a cleavage reaction, *in vitro* translated unlabeled (non-isotopic) hRad21 WT or hRad21 apoptotic cleavage site (ACS) mutants, ACSmut-I or ACSmut-II in the rabbit reticulocyte lysate were incubated with saline (vehicle) (lane a) or with caspase-3 (lane b) or caspase-7 (lane c). TnT reactions in the absence of plasmid DNA served as a negative control. Samples were analyzed on a 6% SDS PAGE followed by Western blotting with hRad21 C-terminal pAb. (B) ³⁵S-hRad21 was incubated in the absence of extract (lane 1) and presence of Molt4 cell lysates treated with DMSO (lane 2) or 10 μ M etoposide for 6h (lane 3). Samples were resolved on a 6% SDS-PAGE gel, fixed with methanol and acetic acid for 30 min, dried on a gel dryer and exposed to a STORM imager.




Fig. 8. Cleavage hRad21 in the Caspase-3 deficient MCF-7 breast cancer cells. Apoptosis was induced by treating MCF-7 cells with 60 μ M etoposide for 6h. Cells treated with DMSO (vehicle) served as a control. Whole cell lysates or lysates from the cytoplasmic and nuclear fractions were electrophoresed on a 6% SDS-PAGE gel and subjected to Western blot analysis using hRad21 mAb. Arrows indicate the hRad21 products.




Fig. 9. C-terminal hRad21 cleavage product promotes apoptosis in Molt4 T-cell leukemia. Molt4 cells were transiently transfected with CMV promoter-driven myc-tagged mammalian expression plasmids encoding the full length hRad21 or cDNAs encoding the two cleavage products, hRad21 N-terminal (aa 1-279) or hRad21 C-terminal (aa 280-631) proteins. Caspase-3 activity was measured as described in the methods section. Data are the averages and standard error of the means from two experiments.




Fig. 10. Effect of p53 status on the cleavage of hRad21. Apoptosis was induced in myeloid leukemia cell lines ML-1 and HL-60 with WT and null p53 genotypes, respectively, by treating the cells with ultraviolet (UV) light (20 J/m²) or ionizing radiation (IR) (20 Gy). Six hour after treatment, protein lysates were made and resolved on a 6% SDS-PAGE followed by Western blot analysis using hRad21 monoclonal antibody. Arrows indicate hRad21 cleavage products. C= control without the UV or IR treatment.




Fig. 11. Model showing the cleavage of the cohesion protein hRad21 and translocation of the C-terminal cleavage product to the cytoplasm early in the apoptotic pathway that amplifies the cell death signal in a positive feed back manner by activating more caspases.

Appendix-III

The Role of Carboxy-Terminal Rad21 in Apoptosis of Breast Cancer Cells

Burley III, Ulysses W., Morehouse College, Class of 2005, Debananda Pati, Ph.D.,
Department of Pediatrics, Oncology, and Hematology, Texas Children's Cancer Center

Genetic instability in the form of aneuploidy is found in a multitude of cancers and is a hallmark feature of hematopoietic cancers such as leukemia and solid malignancies such as breast cancer. The overall objective of Dr. Debananda Pati's lab is to understand how aneuploidy arises at the molecular level. Because aneuploidy often occurs as a result of the loss of coordination between cell division and cell death, we specifically aim to identify proteins incorporated within the mechanisms of cell division, apoptosis, and chromosomal instability in cancer. Our research focuses on the events between the mitotic stages of metaphase, where sister chromatids are held together by cohesin, and anaphase, when proteolytic cleavage of Rad21/SCC1/MCD1, a component of cohesin, by the enzyme separase allows chromosomal separation. Our working hypothesis is that cohesin Rad21/SCC1/MCD1 and associated proteins maintain chromosomal stability and proper chromosomal segregation and that the dysregulation of these proteins results in aberrant cohesion, leading to aneuploidy and more importantly cancer. Recent evidence found in Pati's lab indicates a novel link between the sister chromatid cohesion molecule Rad21 and apoptosis.

The aim of my research this summer was to attempt to answer the question: How does wild type Rad21, and more importantly carboxy-terminal Rad21 induce or amplify apoptosis in breast cancer cells? With existing knowledge of the lab's previous investigations with c-terminal Rad21 and its movement to the cytoplasm, I hypothesized that Rad21, normally a nuclear protein, is cleaved by caspase like enzymes, by which the c-terminal translocates to the cytoplasm inducing or amplifying an apoptotic signal by interacting with proteins in the apoptosis pathway. Because majority of the key events of apoptosis take place in the cytoplasm, I went about testing my hypothesis using the Cytotrap® yeast two hybrid cloning method that detects protein-protein interactions in the cytoplasm. The system uses the yeast *S. cerevisiae* temperature sensitive mutant strain cdc25H, in which the mutation prevents growth at 37°C, however allowing normal growth at 25°C. DNA encoding the protein of interest, in my case c-terminal Rad21, is cloned into the pSOS vector generating a fusion protein of the two. A cDNA library is inserted into the pMyr vector and expressed as a fusion protein with a myristylation sequence that anchors the expressed protein to the membrane. The two plasmids are transformed into the cdc25H yeast, which is then grown at 37°C; in the event that c-terminal Rad21 interacts with target proteins, a cascade of events will allow the cdc25H yeast to grow at 37°C. Currently I am engaging in the cDNA library screening and hope to identify putative positive interactors with c-terminal Rad21.

(Mr. Ulysses Burley III, an undergraduate student of Morehouse College, Atlanta, GA was supported by a summer studentship from the SMART program, funded by the National Institute of Health, National Institute of General Medical sciences to Baylor College of Medicine).